CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure

Abstract

OBJECTIVES: To examine whether endogenous aldosterone can cause either arrhythmias (and some of their underlying mechanisms) or endothelial dysfunction in patients with coronary artery disease (CAD) but without heart failure. BACKGROUND: Aldosterone blockade has been shown to reduce the incidence of sudden death in patients with heart failure. This could be caused by a reduction in arrhythmias or in coronary events. Whether either effect also occurs in other cardiac patients without heart failure is currently unknown. METHOD: We performed a randomized, placebo-controlled, double-blind crossover study on 98 patients with CAD but without heart failure on standard therapy, comparing 12.5-50 mg/day spironolactone (3 months) with placebo. Endothelial function was assessed by bilateral forearm venous occlusion plethysmography. Ventricular extrasystoles, procollagen III N-terminal peptide (PIIINP) and QT interval length were used to represent arrhythmias and their determinants. RESULTS: Spironolactone produced a highly significant 75% reduction in ventricular extrasystoles (median 192, range 48-744) on placebo compared with spironolactone (median 48, range 19.2-288, P < 0.003). Spironolactone also decreased the QT interval from a mean of 440 +/- 28 to a mean of 425 +/- 25 (P < 0.001) and a collagen marker (PIIINP) from a mean of 3.6 +/- 0.9 to a mean of 3.0 +/- 0.8 (P < 0.001), but did not significantly change endothelial dysfunction or heart rate variability. CONCLUSION: These results suggest that despite conventional therapy, endogenous aldosterone can be an arrhythmogenic influence in patients with CAD, but without heart failure. The possible mechanisms are that aldosterone promotes myocardial fibrosis and lengthens the QTc interval as well as decreasing potassium in CAD patients without heart failure.

Overview

Integrity signals

Registry

Crossref · 10.1097/hjh.0b013e3282e9a72d

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 43

Metadata

Authors
Shah, N. C., Pringle, S. D., Donnan, P. T., & Struthers, A. D.
Affiliations
Ninewells Hospital (GB)
Corresponding author
Struthers, Allan D
Venue
Journal of Hypertension
Published
2007-11
Volume
25
Issue
11
Pages
2345-2351
ISSN
0263-6352 (ISSN-L)
OpenAlex
W2038607077
Cited by
43
References
27
Citations by year
2026: 2 · 2025: 1 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 5 · 2014: 6 · 2013: 1 · 2012: 2
FWCI
2.68
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Hypertension (publishedVersion)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion)
Funders
British Heart Foundation
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Keywords
spironolactone, aldosterone blockade, coronary artery disease, ventricular arrhythmias, premature ventricular contractions, QT interval, endothelial dysfunction, myocardial fibrosis, potassium, antiarrhythmic effect
MeSH terms
Aged, Aldosterone, Mineralocorticoid Receptor Antagonists, Anti-Arrhythmia Agents, Arrhythmias, Cardiac, Double-Blind Method, Electrocardiography, Female, Forearm, Humans, Male, Middle Aged, Peptide Fragments, Procollagen, Spironolactone, Myocardial Ischemia, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. https://app.cochat.ai/papers/10.1097/hjh.0b013e3282e9a72d
The paper
Shah, N. C., Pringle, S. D., Donnan, P. T., & Struthers, A. D. (2007). Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. Journal of Hypertension. https://doi.org/10.1097/hjh.0b013e3282e9a72d

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.